Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
about
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
description
A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov
@en
klinisch onderzoek
@nl
name
Pegylated Liposomal Doxorubici ...... , or Primary Peritoneal Cancer
@en
Pegylated Liposomal Doxorubici ...... , or Primary Peritoneal Cancer
@nl
type
label
Pegylated Liposomal Doxorubici ...... , or Primary Peritoneal Cancer
@en
Pegylated Liposomal Doxorubici ...... , or Primary Peritoneal Cancer
@nl
prefLabel
Pegylated Liposomal Doxorubici ...... , or Primary Peritoneal Cancer
@en
Pegylated Liposomal Doxorubici ...... , or Primary Peritoneal Cancer
@nl
P6153
P3098
NCT02839707